Abstract
Since multiple lines of experimental and clinical data clearly identified regulatory T cells as an integral part of the immune response, these cells have become a major focus of investigation in tumor immunology. Regulatory T cells are in place to dampen ongoing immune responses and to prevent autoimmunity, but they also have profound effects in blocking therapeutic anti-tumor activity. Therefore regulatory T cells are seen as a major hurdle that must be overcome in order for cancer immunotherapy to reach its therapeutic potential. Regulatory T cells are heterogeneous with sub-populations that exhibit distinct functional features. Here we will review the individual sub-populations in regards to their mode of action and their potential impact on blocking anti-tumor immunity. Approaches to measure function and frequency of regulatory T cells in model systems and clinical trails will be discussed. Finally, we will describe possible ways to interfere with regulatory T cell-mediated immune suppression with the focus on recent pre-clinical and clinical findings.
Current Molecular Medicine
Title: Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Volume: 9 Issue: 6
Author(s): Sarah Church, Bernard A. Fox, Walter J. Urba, Brendan D. Curti, Hong-Ming Hu, Todd S. Crocenzi, Sidney Rosenheim, Andrew D. Weinberg, Emmanuel Akporiaye, Edwin B. Walker, Daniel P. Haley, Elisa Cardenas, Ulf Petrausch, Kevin Friedman, Levi Maston, Tarsem Moudgil, Michael G. LaCelle, Sachin Puri, Ilka Assmann, James A. Thompson, Chris Twitty, Shawn M. Jensen and Christian H. Poehlein
Affiliation:
Abstract: Since multiple lines of experimental and clinical data clearly identified regulatory T cells as an integral part of the immune response, these cells have become a major focus of investigation in tumor immunology. Regulatory T cells are in place to dampen ongoing immune responses and to prevent autoimmunity, but they also have profound effects in blocking therapeutic anti-tumor activity. Therefore regulatory T cells are seen as a major hurdle that must be overcome in order for cancer immunotherapy to reach its therapeutic potential. Regulatory T cells are heterogeneous with sub-populations that exhibit distinct functional features. Here we will review the individual sub-populations in regards to their mode of action and their potential impact on blocking anti-tumor immunity. Approaches to measure function and frequency of regulatory T cells in model systems and clinical trails will be discussed. Finally, we will describe possible ways to interfere with regulatory T cell-mediated immune suppression with the focus on recent pre-clinical and clinical findings.
Export Options
About this article
Cite this article as:
Church Sarah, Fox A. Bernard, Urba J. Walter, Curti D. Brendan, Hu Hong-Ming, Crocenzi S. Todd, Rosenheim Sidney, Weinberg D. Andrew, Akporiaye Emmanuel, Walker B. Edwin, Haley P. Daniel, Cardenas Elisa, Petrausch Ulf, Friedman Kevin, Maston Levi, Moudgil Tarsem, LaCelle G. Michael, Puri Sachin, Assmann Ilka, Thompson A. James, Twitty Chris, Jensen M. Shawn and Poehlein H. Christian, Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects, Current Molecular Medicine 2009; 9 (6) . https://dx.doi.org/10.2174/156652409788970670
DOI https://dx.doi.org/10.2174/156652409788970670 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Targeting of Apoptotic Pathways: Novel Aspects in Pancreatic Cancer
Current Pharmaceutical Biotechnology Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry HR-MAS NMR Spectroscopy: A Practical Guide for Natural Samples
Current Organic Chemistry Crude Venom from Nematocysts of the Jellyfish Pelagia noctiluca as a Tool to Study Cell Physiology
Central Nervous System Agents in Medicinal Chemistry Urokinase Receptor and Integrin Interactions
Current Pharmaceutical Design A Review on Recent Developments in the Anticancer Potential of Oleanolic Acid and its Analogs (2017-2020)
Mini-Reviews in Medicinal Chemistry Targeting Poly (ADP) Ribose Polymerase I (PARP-1) and PARP-1 Interacting Proteins for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Fluoxetine and all other SSRIs are 5-HT<sub>2B</sub> Agonists - Importance for their Therapeutic Effects
Current Neuropharmacology Finding Recurrent Copy Number Alteration Regions: A Review of Methods
Current Bioinformatics RNA Interference in Cancer: Targeting the Anti-Apoptotic Protein c-FLIP for Drug Discovery
Mini-Reviews in Medicinal Chemistry Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
Current Genomics Nanotechnology and Brain Tumors Drug Delivery
Recent Patents on Nanomedicine Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry CD44 and EpCAM: Cancer-Initiating Cell Markers
Current Molecular Medicine Targeting the BRCA1/2 Tumor Suppressors
Current Drug Targets Imaging of Integrins as Biomarkers for Tumor Angiogenesis
Current Pharmaceutical Design Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective
Current Pharmaceutical Design Oxazole-Based Compounds As Anticancer Agents
Current Medicinal Chemistry The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry